Suppr超能文献

突变型超氧化物歧化酶1酶的生化/生物物理特性变化与家族性肌萎缩侧索硬化家系疾病进展速率的关系。

Variation in the biochemical/biophysical properties of mutant superoxide dismutase 1 enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds.

作者信息

Ratovitski T, Corson L B, Strain J, Wong P, Cleveland D W, Culotta V C, Borchelt D R

机构信息

Department of Pathology, Johns Hopkins School of Medicine, 558 Ross Building, 720 Rutland Avenue, Baltimore, MD 21205, USA,

出版信息

Hum Mol Genet. 1999 Aug;8(8):1451-60. doi: 10.1093/hmg/8.8.1451.

Abstract

Mutations in superoxide dismutase 1 (SOD1) polypeptides cause a form of familial amyotrophic lateral sclerosis (FALS). In different kindreds, harboring different mutations, the duration of illness tends to be similar for a given mutation. For example, patients inheriting a substitution of valine for alanine at position four (A4V) average a 1.5 year life expectancy after the onset of symptoms, whereas patients harboring a substitution of arginine for histidine at position 46 (H46R) average an 18 year life expectancy after disease onset. Here, we examine a number of biochemical and biophysical properties of nine different FALS variants of SOD1 polypeptides, including enzymatic activity (which relates indirectly to the affinity of the enzyme for copper), polypeptide half-life, resistance to proteolytic degradation and solubility, in an effort to determine whether a specific property of these enzymes correlates with clinical progression. We find that although all the mutants tested appear to be soluble, the different mutants show a remarkable degree of variation with respect to activity, polypeptide half-life and resistance to proteolysis. However, these variables do not stratify in a manner that correlates with clinical progression. We conclude that the basis for the different life expectancies of patients in different kindreds of sod1-linked FALS may result from an as yet unidentified property of these mutant enzymes.

摘要

超氧化物歧化酶1(SOD1)多肽的突变会导致一种家族性肌萎缩侧索硬化症(FALS)。在携带不同突变的不同家族中,对于给定的突变,疾病持续时间往往相似。例如,继承了第4位缬氨酸替代丙氨酸(A4V)突变的患者,症状出现后的平均预期寿命为1.5年,而携带第46位组氨酸替代精氨酸(H46R)突变的患者,疾病发作后的平均预期寿命为18年。在此,我们研究了SOD1多肽的九种不同FALS变体的一些生化和生物物理特性,包括酶活性(这与酶对铜的亲和力间接相关)、多肽半衰期、对蛋白水解降解的抗性和溶解度,以确定这些酶的特定特性是否与临床进展相关。我们发现,尽管所有测试的突变体似乎都是可溶的,但不同的突变体在活性、多肽半衰期和对蛋白水解的抗性方面表现出显著的差异。然而,这些变量并没有以与临床进展相关的方式分层。我们得出结论,sod1相关FALS不同家族中患者预期寿命不同的原因可能是这些突变酶尚未确定的特性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验